Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435522 · ClinicalTrials.gov registry record · Phase 1
Maraviroc in Patients With Moderate and Severe COVID-19
A Phase 1 study, sponsored by Rhode Island Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04435522 is a Phase 1 study that has completed, run by Rhode Island Hospital. The registered enrollment target is 9 participants.
The verdict
NCT04435522, a Phase 1 study, has completed, sponsored by Rhode Island Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell trafficking of inflammatory cells, both increasing viral control capacity and dampening damage to lung tissue, respectively. This study seeks to establish whether one week of treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.
Interventions
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04435522
The ClinicalTrials.gov registry entry for NCT04435522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maraviroc is the first listed.
NCT04435522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04435522 about?
NCT04435522 is a clinical study titled "Maraviroc in Patients With Moderate and Severe COVID-19". Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV. CCR5 antagonism prior to the 'second wave' of inflammatory mediator expression in SARS-CoV-2 may reverse lymphoid depletion and may alter cell traffick...
What is the current status of trial NCT04435522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-10-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04435522?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT04435522?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.